Bio Ring Diagnostics

Projektinformationen

Bio Ring Diagnostics

ID Finanzhilfevereinbarung: 866899

DOI

10.3030/866899

Projekt abgeschlossen

EK-Unterschriftsdatum 11 Mai 2019

Startdatum 1 Juni 2019

Enddatum 30 November 2019

Finanziert unter

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

DELTA DIAGNOSTICS BV
Netherlands

Periodic Reporting for period 1 - Bio Ring Diagnostics (Bio Ring Diagnostics)

Berichtszeitraum: 2019-06-01 bis 2019-11-30

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Delta Diagnostics develops biosensors based on integrated optical chips for various applications in life-science research and point-of-care diagnostics. There is a growing need for affordable label-free biosensing instruments for research, as well as novel sensitive and highly-multiplexed point-of-care diagnostic tests. We aim to make sensitive, multiplexed, label-free biosensing accessible to all. During the SMEi phase 1 project, the feasibility of our business idea was determined by reaching the following objectives:
• Objective 1: Market analysis and business plan
• Objective 2: Description of technical concepts/ design of principal technology platform and architecture for the MVP.
• Objective 3: Partner search
• Objective 4: Commercial and legal strategy

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

We have performed a thorough market analysis and had a large number of meetings with potential customers, suppliers and other stakeholders. We drafted a business plan for the development and marketing of our first and subsequent products. Research on the technical feasibility was performed, leading to a highly innovative instrument architecture and a functioning prototype. The economic feasibility was confirmed, a.o. via a bill-of material analysis and development of a pricing strategy.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

Conclusions of the SMEi feasibility study:
- There is an unmet need for label-free detection technology for point of care diagnostics. Current label-free technology is not suitable for use outside the lab.
- The fact that with our technology we can make a smooth transition from lab-developed assay to point-of-care test is highly valued by many potential customers.
- The developed strategy is commercially viable.
- Technical viability has been proven through the realization of a prototype, based in a novel instrument architecture.
- The results of the SMEi feasibility study have helped Delta Diagnostics to secure funding for a validation project in which the technology will be internally and externally validated.
- As result of the positive outcome of the SMEi feasibility study, we intent to apply for SMEi phase 2 funding to advance from prototype to final product.

rings.jpg